Brian Guan-Chyun Liu

CIK: 0002007835

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CGON

CG Oncology, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CGON
CG Oncology, Inc.
Jun 25, 2026
Purchase(P)
Indirect
371.1K shares at avg. $66.87$24.8M
CGON
CG Oncology, Inc.
Jun 4, 2026
Award(A)
Director Stock Option (right to buy)
Direct
9.4K shares-
CGON
CG Oncology, Inc.
Sep 11, 2025
Purchase(P)
Indirect
1.5M shares at avg. $33.00$50.0M
CGON
CG Oncology, Inc.
Jun 5, 2025
Award(A)
Director Stock Option (right to buy)
Direct
24.2K shares-
CGON
CG Oncology, Inc.
Oct 4, 2024
Award(A)
Stock Option (Right to Buy)
Direct
15.6K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	CGON CG Oncology, Inc.	Purchase(P)	371,085	$66.87	$24,814,454	Indirect
Jun 4, 2026	CGON CG Oncology, Inc.	Award(A) Director Stock Option (right to buy)	9,354	-	-	Direct
Sep 11, 2025	CGON CG Oncology, Inc.	Purchase(P)	1,515,151	$33.00	$49,999,983	Indirect
Jun 5, 2025	CGON CG Oncology, Inc.	Award(A) Director Stock Option (right to buy)	24,165	-	-	Direct
Oct 4, 2024	CGON CG Oncology, Inc.	Award(A) Stock Option (Right to Buy)	15,600	-	-	Direct

1-5 of 5 transactions

About Liu Brian Guan-Chyun

Liu Brian Guan-Chyun (SEC CIK 0002007835) files insider reports with the SEC as Director of CG Oncology, Inc. (CGON).

Signal8 holds 5 ownership filings by Liu Brian Guan-Chyun, all Form 4s, filed between Oct 7, 2024 and Jun 29, 2026. Those filings report 5 transactions, from Oct 4, 2024 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Liu Brian Guan-Chyun's filings is in DALLAS, TX.

Recent filings by Liu Brian Guan-Chyun

Jun 25, 2026: Open-market purchase of CGON shares (Form 4, code P).
Jun 4, 2026: Grant or award of CGON derivative securities (Form 4, code A).
Sep 11, 2025: Open-market purchase of CGON shares (Form 4, code P).
Jun 5, 2025: Grant or award of CGON derivative securities (Form 4, code A).
Oct 4, 2024: Grant or award of CGON derivative securities (Form 4, code A).

Other insiders filing for CG Oncology, Inc. (CGON)

Kalofonos Isabel, Chief Commercial Officer
POST LEONARD E, Director
Mulay James, Director
Tong Victor Edward Jr, Director
Rossi Christina, Director
Graf Susan E, Director

How to read Form 4 transaction codes